Cowen Lowers Science 37 (NASDAQ:SNCE) Price Target to $3.00

Science 37 (NASDAQ:SNCEGet Rating) had its price target reduced by equities research analysts at Cowen from $7.00 to $3.00 in a research note issued on Monday, The Fly reports. The firm currently has an “outperform” rating on the stock. Cowen’s price objective points to a potential upside of 256.55% from the stock’s current price.

A number of other research analysts have also recently weighed in on SNCE. Craig Hallum dropped their price target on Science 37 to $7.00 in a research report on Monday, August 15th. Robert W. Baird dropped their price target on Science 37 from $6.00 to $2.00 in a research report on Friday, November 11th. Finally, Cowen dropped their price target on Science 37 to $7.00 in a research report on Monday, August 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Science 37 Stock Performance

Science 37 stock opened at $0.84 on Monday. Science 37 has a one year low of $0.81 and a one year high of $14.44. The business has a fifty day moving average of $1.50 and a two-hundred day moving average of $2.19. The company has a market cap of $98.16 million, a P/E ratio of -1.68 and a beta of 1.27.

Institutional Trading of Science 37

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. purchased a new stake in Science 37 in the 1st quarter valued at about $37,000. Virtu Financial LLC purchased a new stake in Science 37 in the 1st quarter valued at about $60,000. Strs Ohio purchased a new stake in Science 37 in the 2nd quarter valued at about $29,000. JPMorgan Chase & Co. grew its holdings in Science 37 by 29.0% in the 1st quarter. JPMorgan Chase & Co. now owns 14,574 shares of the company’s stock valued at $78,000 after buying an additional 3,272 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in Science 37 in the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 58.60% of the company’s stock.

Science 37 Company Profile

(Get Rating)

Science 37 Holdings, Inc provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data.

See Also

The Fly logo

Analyst Recommendations for Science 37 (NASDAQ:SNCE)

Receive News & Ratings for Science 37 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science 37 and related companies with MarketBeat.com's FREE daily email newsletter.